Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis B and C impact targets to demonstrate elimination, whilst highlighting challenges caused by high disease burden in some countries, as well as delays in reaching mortality targets due to the long natural history of disease progression to liver cirrhosis and hepatocellular carcinoma.
Driving Elimination through HCV Case Finding in Primary Care
Download
On 12th September 2022, Merck Sharp & Dohme (MSD) convened a roundtable bringing together some of the
country’s leading healthcare professionals. The purpose of the roundtable was to provide a forum to discuss
the ways in which HCV case finding could be improved and increase the uptake and use of the Patient Search
Identification (PSI) software.
The PSI software is a case-finding tool which searches for coded HCV risk factors in patient records in primary care
settings to identify potentially at-risk patients that should be reviewed and, if appropriate, tested.
‘Driving Elimination through HCV Case Finding in Primary Care’ shines a light on the best approaches to empowering
Healthcare Professionals and third sector organisations with the tools needed to tackle HCV rates in England. The
convened experts came up with eight recommendations which would bring improvements to the pathway, which are
summarised in this report.
